Jenburkt Pharmaceuticals Ltd

JENBURPH

Watchlist

AI Mode

‌

Market Cap

₹ 487 Cr

P/E

14.77

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

HIGH MARGIN

Technicals

Bearish

Risk

LOW RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Jenburkt Pharmaceuticals Ltd is a company engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products both in India and internationally.

The company operates a manufacturing plant in Gujarat that complies with WHO guidelines, demonstrating its commitment to quality and global standards.

Jenburkt has a vast distribution network of over 1,000 stockists, extending its reach to more than 400,000 pharmacies globally.

In recent years, the company diversified into the OTC market with the launch of its Jenburkt Wellness division, introducing products like Zixa Strong and Nervijen D3.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

487 Cr

Volatility

Low Risk

P/E Ratio

14.8

Industry P/E

43.8

PEG Ratio

1.1

P/B Ratio

2.7

52W High

1,410.00

52W Low

936.70

Sales CAGR

6.85%

6.96%

4.99%

10Y

5.34%

Profit CAGR

23.40%

12.87%

16.61%

10Y

12.88%

ROE

TTM

18.04%

18.82%

18.54%

10Y

20.41%

ROCE

TTM

24.68%

25.01%

24.44%

10Y

27.57%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
KILITCH	334.00	586 Cr	21.27	2.21	0.00	10.38	11.71	6.55
MEDICAMEQ	390.70	539 Cr	50.38	1.96	0.24	3.88	4.69	2.31
INFLUX	231.00	535 Cr	40.03	6.36	0.00	0.00	0.00	15.55
JENBURPH	1090.00	487 Cr	14.77	2.67	1.63	18.04	24.68	15.78
KERALAYUR	335.00	404 Cr	—	74.02	0.00	-417.29	-15.11	-16.54
BAFNAPH	149.00	352 Cr	33.33	3.86	0.00	11.59	11.00	5.46
ZENOTECH	46.36	285 Cr	99.32	2.96	0.00	3.19	9.08	2.77

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	29	38	36	39	33	41	37	41	36	46
Expenses	22	29	28	29	23	30	28	30	27	32
Operating Profit	6.97	9.10	7.20	9.85	9.29	11	8.82	11	8.96	13
OPM %	23.89	23.77	20.19	25.36	28.55	27.73	23.91	26.46	25.22	28.75
Other Income	1.04	1.10	1.35	1.19	1.41	1.85	1.58	1.88	2.06	2.08
Interest	0.07	0.07	0.07	0.06	0.11	0.12	0.11	0.11	0.11	0.11
Depreciation	0.50	0.59	0.63	0.62	0.52	0.64	0.78	0.79	0.72	0.74
Profit Before Tax	7.43	9.54	7.84	10	10	13	9.51	12	10	14
Tax %	27.73	23.27	31.12	23.92	26.34	23.32	31.65	27.87	23.48	29.10
Net Profit	5.37	7.32	5.40	7.88	7.42	9.60	6.51	8.54	7.79	10
EPS in Rs	12.17	16.59	12.25	17.86	16.80	21.75	14.75	19.34	17.66	23.03

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	105	115	123	119	109	124	137	142	152	155
Expenses	84	91	98	99	89	97	106	109	111	115
Operating Profit	21	24	25	20	20	27	30	33	40	40
OPM %	20.33	20.96	20.35	16.61	18.15	21.98	22.21	23.33	26.63	25.90
Other Income	2.96	3.39	3.41	4.22	4.31	4.95	5.12	4.67	6.72	7.37
Interest	0.41	0.41	0.39	0.53	0.47	0.43	0.37	0.27	0.45	0.45
Depreciation	1.79	1.50	1.35	2.30	2.04	1.90	2.26	2.34	2.73	2.93
Profit Before Tax	20	25	27	21	22	30	33	35	44	44
Tax %	34.04	31.88	25.67	29.65	23.75	25.35	25.13	26.15	27.02	26.36
Net Profit	14	17	20	15	17	22	25	26	32	32
EPS in Rs	30.91	39.13	44.86	33.69	37.41	50.52	55.21	58.87	72.64	74.78
Dividend Payout %	27.88	24.00	23.64	25.00	28.36	24.70	26.72	25.99	24.78	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	4.65	4.65	4.59	4.59	4.59	4.59	4.59	4.41	4.41	4.41
Reserves	36	50	57	73	75	94	113	118	141	167
Borrowings	5.42	6.37	0.24	7.47	3.44	5.07	6.76	2.93	0.00	3.89
Other Liabilities	12	16	16	18	21	18	19	16	20	21
Total Liabilities	58	76	77	103	104	121	143	142	165	196
Fixed Assets	12	11	9.57	9.59	12	11	11	10	10	15
CWIP	0.00	0.00	0.00	0.99	0.12	0.38	0.21	0.96	1.24	40
Investments	0.61	1.94	5.42	5.38	4.07	6.75	7.96	11	17	21
Other Assets	45	64	62	87	88	104	123	119	137	121
Total Assets	58	76	77	103	104	121	143	142	165	196

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	7.82	9.95	16	13	15	19	9.27	17	8.12	28
Cash from Investing Activity	-0.27	-9.77	1.00	-11	-2.88	-19	-1.20	2.62	-0.58	-17
Cash from Financing Activity	-5.42	0.68	-18	-2.42	-11	-0.71	-5.53	-21	-7.08	-7.62
Net Cash Flow	2.13	0.86	-0.80	0.04	1.31	-0.04	2.54	-1.37	0.47	3.24

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	45.97%	47.56%	47.56%	47.42%	47.39%	47.23%	46.71%	46.71%	46.69%	46.68%	46.67%	46.66%
FIIs	3.49%	2.70%	1.79%	1.38%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.12%	0.12%	0.12%	0.12%
Public	50.54%	49.74%	50.65%	51.21%	52.61%	52.77%	53.29%	53.29%	53.20%	53.20%	53.22%	53.22%
Total Shareholders	5,784	5,611	5,741	5,872	6,021	6,316	6,419	6,628	6,901	6,987	6,712	6,855

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Jun 14, 2024	Prakash h. bhuta	Insider - Promoter Group	Disposal	804.79	1.65 Cr	20,473	0.46
Mar 27, 2024	Prakash bhuta	Insider - Promoter Group	Disposal	702.21	0.42 Cr	5,931	0.13
Jul 10, 2023	Mahesh h bhuta	Insider - Promoter Group	Acquisition	—	—	2,500	0.05
Jul 10, 2023	Mahesh h bhuta	Insider - Promoter Group	Disposal	—	—	2,500	0.05
Jul 10, 2023	Mahesh h bhuta	Insider - Promoter Group	Disposal	716.05	0.07 Cr	1,000	0.02
May 29, 2023	Riddhi haresh shroff	Insider - Promoter Group	Acquisition	—	—	14,707	0.33
May 29, 2023	Riddhi haresh shroff	Insider - Promoter Group	Disposal	—	—	14,707	0.33
Apr 26, 2023	Riddhi haresh shroff	Insider - Promoter Group	Acquisition	—	—	14,707	0.33
Apr 26, 2023	Riddhi haresh shroff	Insider - Promoter Group	Disposal	—	—	14,707	0.33
Jan 06, 2023	Jenburkt pharmaceuticals ltd	Bulk	Buy	649.97	3.06 Cr	47,037	1.06

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	29	38	36	39	33	41	37	41	36	46
Expenses	22	29	28	29	23	30	28	30	27	32
Operating Profit	6.97	9.10	7.20	9.85	9.29	11	8.82	11	8.96	13
OPM %	23.89	23.77	20.19	25.36	28.55	27.73	23.91	26.46	25.22	28.75
Other Income	1.04	1.10	1.35	1.19	1.41	1.85	1.58	1.88	2.06	2.08
Interest	0.07	0.07	0.07	0.06	0.11	0.12	0.11	0.11	0.11	0.11
Depreciation	0.50	0.59	0.63	0.62	0.52	0.64	0.78	0.79	0.72	0.74
Profit Before Tax	7.43	9.54	7.84	10	10	13	9.51	12	10	14
Tax %	27.73	23.27	31.12	23.92	26.34	23.32	31.65	27.87	23.48	29.10
Net Profit	5.37	7.32	5.40	7.88	7.42	9.60	6.51	8.54	7.79	10
EPS in Rs	12.17	16.59	12.25	17.86	16.80	21.75	14.75	19.34	17.66	23.03

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	105	115	123	119	109	124	137	142	152	155
Expenses	84	91	98	99	89	97	106	109	111	115
Operating Profit	21	24	25	20	20	27	30	33	40	40
OPM %	20.33	20.96	20.35	16.61	18.15	21.98	22.21	23.33	26.63	25.90
Other Income	2.96	3.39	3.41	4.22	4.31	4.95	5.12	4.67	6.72	7.37
Interest	0.41	0.41	0.39	0.53	0.47	0.43	0.37	0.27	0.45	0.45
Depreciation	1.79	1.50	1.35	2.30	2.04	1.90	2.26	2.34	2.73	2.93
Profit Before Tax	20	25	27	21	22	30	33	35	44	44
Tax %	34.04	31.88	25.67	29.65	23.75	25.35	25.13	26.15	27.02	26.36
Net Profit	14	17	20	15	17	22	25	26	32	32
EPS in Rs	30.91	39.13	44.86	33.69	37.41	50.52	55.21	58.87	72.64	74.78
Dividend Payout %	27.88	24.00	23.64	25.00	28.36	24.70	26.72	25.99	24.78	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	4.65	4.65	4.59	4.59	4.59	4.59	4.59	4.41	4.41	4.41
Reserves	36	50	57	73	75	94	113	118	141	167
Borrowings	5.42	6.37	0.24	7.47	3.44	5.07	6.76	2.93	0.00	3.89
Other Liabilities	12	16	16	18	21	18	19	16	20	21
Total Liabilities	58	76	77	103	104	121	143	142	165	196
Fixed Assets	12	11	9.57	9.59	12	11	11	10	10	15
CWIP	0.00	0.00	0.00	0.99	0.12	0.38	0.21	0.96	1.24	40
Investments	0.61	1.94	5.42	5.38	4.07	6.75	7.96	11	17	21
Other Assets	45	64	62	87	88	104	123	119	137	121
Total Assets	58	76	77	103	104	121	143	142	165	196

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	7.82	9.95	16	13	15	19	9.27	17	8.12	28
Cash from Investing Activity	-0.27	-9.77	1.00	-11	-2.88	-19	-1.20	2.62	-0.58	-17
Cash from Financing Activity	-5.42	0.68	-18	-2.42	-11	-0.71	-5.53	-21	-7.08	-7.62
Net Cash Flow	2.13	0.86	-0.80	0.04	1.31	-0.04	2.54	-1.37	0.47	3.24

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
KILITCH	334.00	586 Cr	21.27	2.21	0.00	10.38	11.71	6.55
MEDICAMEQ	390.70	539 Cr	50.38	1.96	0.24	3.88	4.69	2.31
INFLUX	231.00	535 Cr	40.03	6.36	0.00	0.00	0.00	15.55
JENBURPH	1090.00	487 Cr	14.77	2.67	1.63	18.04	24.68	15.78
KERALAYUR	335.00	404 Cr	—	74.02	0.00	-417.29	-15.11	-16.54
BAFNAPH	149.00	352 Cr	33.33	3.86	0.00	11.59	11.00	5.46
ZENOTECH	46.36	285 Cr	99.32	2.96	0.00	3.19	9.08	2.77

Overview

Detailed Summary

Jenburkt Pharmaceuticals Ltd is a company engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products both in India and internationally.

The company operates a manufacturing plant in Gujarat that complies with WHO guidelines, demonstrating its commitment to quality and global standards.

Jenburkt has a vast distribution network of over 1,000 stockists, extending its reach to more than 400,000 pharmacies globally.

In recent years, the company diversified into the OTC market with the launch of its Jenburkt Wellness division, introducing products like Zixa Strong and Nervijen D3.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

487 Cr

Volatility

Low Risk

P/E Ratio

14.8

Industry P/E

43.8

PEG Ratio

1.1

P/B Ratio

2.7

52W High

1,410.00

52W Low

936.70

Sales CAGR

6.85%

6.96%

4.99%

10Y

5.34%

Profit CAGR

23.40%

12.87%

16.61%

10Y

12.88%

ROE

TTM

18.04%

18.82%

18.54%

10Y

20.41%

ROCE

TTM

24.68%

25.01%

24.44%

10Y

27.57%